An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6963
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer ; volume:22 ; number:1 ; day:23 ; month:11 ; year:2022 ; pages:1-8 ; date:12.2022
BMC health services research ; 22, Heft 1 (23.11.2022), 1-8, 12.2022
- Creator
-
Paladino, Andrew J.
Pebley, Kinsey
Kocak, Mehmet
Krukowski, Rebecca A.
Waters, Teresa M.
Vidal, Gregory
Schwartzberg, Lee
Curry, Andrea N.
Graetz, Ilana
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12913-022-08705-9
- URN
-
urn:nbn:de:101:1-2023020509005995220320
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Paladino, Andrew J.
- Pebley, Kinsey
- Kocak, Mehmet
- Krukowski, Rebecca A.
- Waters, Teresa M.
- Vidal, Gregory
- Schwartzberg, Lee
- Curry, Andrea N.
- Graetz, Ilana
- SpringerLink (Online service)
Other Objects (12)
Rat Models of Hormone Receptor-Positive Breast Cancer
The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis